Fig. 1
From: Vaccination with nanoparticles combined with micro-adjuvants protects against cancer
CuMVTT-VLPs demonstrate fast kinetics and constitute an efficient vaccine platform for displaying target peptides/epitopes. a Electron microscopy imaging of CuMVTT-VLPs, (3.5 mg/ml) adsorped on carbon grids and negatively stained with uranyl acetate solution, scale bar 200 nm, CuMVTT-VLPs sized ∼30 nm. b Stereomicroscopy images of mice popliteal LN following s.c. injection of AF488 CuMVTT-VLPs in mice footpad. [1] bright field of the popliteal LN (identified by the arrowhead) [2] fluorescent image prior to injection of AF488 CuMVTT-VLPs, [3,4,5] 1 min, 5 min and 10 min post injection of AF488 CuMVTT-VLPs taken with the appropriate fluorescent filters. c A sketch illustrating the coupling of p33 epitope to CuMVTT-VLPs using Cu-free click chemistry (Dibenzocyclooctyne-N-hydroxysuccinimidyl ester (DBCO) cross-linker). DBCO cross-linker reacts with Lys residues on CuMVTT-VLPs and incorporates a cyclooctyne moiety. The formed dibenzocyclooctyne will then react with azide-labelled p33 peptide forming a stable triazole linkage without Cu catalyst. d SDS-PAGE of CuMVTT-p33 nano-vaccine using DBCO “Dibenzocyclooctyne-N-hydroxysuccinimidyl ester” cross-linker; arrows indicate CuMVTT-VLP monomers and dimers (formed by DBCO cross-linking of 2 monomers) with coupled p33 peptide